DexCom (NASDAQ:DXCM) EVP Sadie Stern Sells 2,565 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction on Monday, September 28th. The shares were sold at an average price of $86.15, for a total value of $220,974.75. Following the sale, the executive vice president directly owned 123,478 shares of the company’s stock, valued at approximately $10,637,629.70. This trade represents a 2.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sadie Stern also recently made the following trade(s):

• On Thursday, August 27th, Sadie Stern sold 2,565 shares of DexCom stock. The shares were sold at an average price of $88.37, for a total transaction of $226,669.05.

DexCom Stock Down 0.4%

NASDAQ DXCM traded down $0.35 during midday trading on Wednesday, hitting $86.29. 3,403,851 shares of the company traded hands, compared to its average volume of 5,087,884. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The company has a market cap of $32.56 billion, a PE ratio of 34.11, a price-to-earnings-growth ratio of 1.45 and a beta of 1.42. The company’s 50-day simple moving average is $85.81 and its 200-day simple moving average is $74.17. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm’s revenue was up 13.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.48 earnings per share. As a group, equities research analysts forecast that DexCom, Inc. will post 2.64 earnings per share for the current year.

Institutional Trading of DexCom

Institutional investors and hedge funds have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB increased its stake in DexCom by 15.4% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after buying an additional 153 shares in the last quarter. V Square Quantitative Management LLC lifted its position in shares of DexCom by 1.8% in the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after acquiring an additional 172 shares in the last quarter. Essex Financial Services Inc. boosted its stake in shares of DexCom by 5.7% in the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after acquiring an additional 175 shares during the last quarter. One Wealth Map LLC raised its stake in DexCom by 5.6% in the 1st quarter. One Wealth Map LLC now owns 4,900 shares of the medical device company’s stock valued at $301,000 after purchasing an additional 261 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its holdings in DexCom by 2.4% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 14,350 shares of the medical device company’s stock valued at $966,000 after purchasing an additional 340 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on DXCM shares. Weiss Ratings raised DexCom from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. BTIG Research reiterated a “buy” rating and issued a $90.00 target price (up from $80.00) on shares of DexCom in a research report on Friday, July 31st. UBS Group set a $96.00 price target on shares of DexCom and gave the stock a “buy” rating in a report on Tuesday, July 28th. Wall Street Zen raised shares of DexCom from a “hold” rating to a “buy” rating in a research report on Sunday, September 6th. Finally, Wells Fargo & Company lifted their price objective on shares of DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $89.08.

DexCom Company Profile

DexCom, Inc (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.